Islet transplantation is promising to be capable of relieving glucose instability and improving QOL of type 1 diabetic patients whose severe hypoglycemic unawareness cannot be controlled. In Japan, a phase II clinical trial of islet transplantation for type 1 diabetes patients has been started using ATG induction and a TNF-α inhibition protocol. Primary endpoints for this trial are the proportion of subjects with HbA1c.
展开▼
